glp-1 receptor agonist kidney outcomes semaglutide flow trial 2024 results FLOW: outcome for GLP-1RA Association of glucagon-like peptide-1 receptor
Description
2023;133:e167700
Tirzepatide was groundbreaking as the first dual GIP/GLP-1 receptor agonist, but it is no longer the only advanced option available
Consistent with this, glucagon-stimulation of insulin secretion is decreased in islets isolated from -cell-specific GLP-1R KO mice [173]
Systemic Sclerosis and DPP4 Scleroderma, also known as systemic sclerosis (SSc), is a severe autoimmune disease characterized by significant fibrosis affecting the skin and internal organs
PMID: 17327526
Between September and October 2024, adults aged 18 years or older who had used a GLP-1RA for at least a month were recruited
